JP Morgan analyst Chris Schott maintains Viatris (NASDAQ:VTRS) with a Neutral and raises the price target from $13 to $14.
IGC CEO Ram Mukunda Posted a Letter to Shareholders Regarding Progress On Co’s Investigational New Drug IGC-AD1 for Alzheimer’s Disease
https://igcinc.us/letter-to-our-shareholders/